Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RORA | P35398 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18156908 | 0.91 | TSHR (0.53) | RORCTSHRMEN1KMT2AMAPT | |
| SCHEMBL18151833 | 0.89 | RORC (0.61) | RORCMEN1KMT2AMAPTRORA | |
| SCHEMBL18151719 | 0.87 | RORC (0.77) | RORCTSHRMEN1KMT2AMAPT | |
| SCHEMBL18151622 | 0.86 | RORC (0.53) | RORCMEN1KMT2AMAPTRORA | |
| SCHEMBL18151624 | 0.84 | RORC (0.60) | RORCMEN1KMT2AMAPTLMNA | |
| SCHEMBL18151519 | 0.84 | RORC (0.54) | RORCMEN1KMT2AMAPTLMNA | |
| SCHEMBL18151831 | 0.82 | RORC (0.53) | RORCMEN1KMT2AMAPTLMNA | |
| SCHEMBL18156912 | 0.80 | RORC (0.49) | RORCMEN1KMT2AMAPTLMNA | |
| SCHEMBL18156927 | 0.79 | PDK1 (0.48) | RORCMEN1KMT2AMAPTLMNA | |
| SCHEMBL17114492 | 0.77 | RORC (1.00) | RORCRORA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980353-B | ROR gamma modulators | 领先制药控股公司 | 2019-06-14 | — | — | CN | claimed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | claimed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | claimed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | claimed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | RORC 1/4885TSHR 167/4885MEN1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.